For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.

Device Registry Required to Determine Efficacy of Newest Prostate Cancer Treatment

Men diagnosed with prostate cancer in the United States now have another treatment option: high-intensity focused ultrasound (HIFU). However, the jury is out in terms of the effectiveness of the treatment, according to Weill Cornell Medicine researchers. In a paper published June 28 in JAMA, they recommend that registries should be created to generate the data and evaluate cancer control and safety.

Read full article.

Population Health Sciences 402 E. 67th St. New York, NY 10065 Phone: (646) 962-8078